Lessons from HIV that can be applied to COVID

Carlos del Rio, MD is a Distinguished Professor of Medicine in the Division of Infectious Diseases at Emory University School of Medicine and Executive Associate Dean for Emory at Grady, Professor of Global Health and of Epidemiology at the Rollins School of Public Health. He is co-Director of the Emory Center for AIDS Research (CFAR) and co-PI of the Emory-CDC HIV Clinical Trials Unit and the Emory Vaccine and Treatment Evaluation Unit.  A native of Mexico, he attended medical school at Universidad La Salle, graduating in 1983.  His Internal Medicine and Infectious Diseases residencies were completed at Emory University.  From 2001 – 2009 he was Emory’s Chief of Medicine at Grady Memorial Hospital then Chair of the Hubert Department of Global Health from 2009 - 2019. 


Dr. del Rio’s research focuses on the early diagnosis, access to care, engagement in care, compliance with antiretrovirals and the prevention of HIV infection.  He has worked for over a decade with hard-to-reach populations, including substance users, to improve outcomes of those infected with HIV and to prevent infection with those at risk. He is also interested in the translation of research findings into practice and policy. Dr. del Rio was a member of the WHO Influenza A(H1N1) Clinical Advisory Group and of the CDC Influenza A(H1N1) Task Force during the 2009 pandemic. 


During the COVID-19 pandemic Dr. del Rio has been a leader locally and nationally, doing research, developing policies, writing scientific publications and making countess media appearances.  He has advised municipal, state, and national leaders including Atlanta Mayor Keisha Lance Bottoms, Tyler Perry Studios, the NCAA, the USTA, Delta Air Lines, Truist Bank, the Atlanta Symphony Orchestra and the Atlanta Opera among others. He also serves on the national advisory committee of the COVID Collaborative, which focuses on developing consensus recommendations and engaging with U.S. leaders on effective policy and coronavirus response.  He is an investigator on the Moderna COVID-19 vaccine clinical trial as well as on the ACTT Studies that led to the approval of Remdesivir among other drugs.